首次授予相关事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性、完整性承担法律责任。 重要内容提示（简称同正文） ●首次授予调整：建议承授人由 201 名调整为 195 名、所涉 H 股受限制股份 单位数量由 10,696,400 份调整为 10,589,500 份 ●首次授予日：2025 年 11 月 4 日 证券代码：600196 证券简称：复星医药 公告编号：临 2025-172 上海复星医药（集团）股份有限公司 关于 2025 年 H 股受限制股份单位计划 ●首次授予 H 股受限制股份单位数量：10,589,500 份 一、2025 年 H 股受限制股份单位计划已履行的决策程序和信息披露情况 （一）2025 年 8 月 22 日，上海复星医药（集团）股份有限公司（以下简称 "本公司"或"复星医药"）第十届董事会第七次会议审议通过关于《上海复星 医药（集团）股份有限公司 2025 年 H 股受限制股份单位计划（草案）》（以下简 称"2025 年 H 股受限制股份单位计划"或"本次激励计划"）、根据该计划向合 资格雇员作出首次授予的议案 ...

表决结果：同意 6 票，反对 0 票，弃权 0 票。 本议案在提交董事会审议前，已经董事会薪酬与考核委员会审核通过。 详情请见同日发布之《关于 2025 年 A 股股票期权激励计划首次授予调整及 证券代码：600196 证券简称：复星医药 公告编号：临 2025-170 上海复星医药（集团）股份有限公司 第十届董事会第十四次会议（临时会议）决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海复星医药（集团）股份有限公司（以下简称"本公司"）第十届董事会 第十四次会议（临时会议）于 2025 年 11 月 4 日召开，全体董事以通讯方式出席 了会议。本次会议的召开符合《中华人民共和国公司法》、其他有关法律法规和 《上海复星医药（集团）股份有限公司章程》的规定。会议审议并达成如下决议： 一、审议通过关于 2025 年 A 股股票期权激励计划首次授予相关事项的议案。 1、根据本公司 2025 年第一次临时股东会（以下简称"股东会"）已审议通 过之《上海复星医药（集团）股份有限公司 2025 年 A 股股票期权激励计划》（以 ...

上海复星医药（集团）股份有限公司 董事会薪酬与考核委员会 关于 2025 年 A 股股票期权激励计划首次授予相关事项的核查意见 上海复星医药（集团）股份有限公司（以下简称"本公司"）董事会薪酬与 考核委员会依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》 （以下简称"《管理办法》"）等相关法律法规及规范性文件和《上海复星医药 （集团）股份有限公司章程》（以下简称"《公司章程》"）的有关规定，对《上 海复星医药（集团）股份有限公司 2025 年 A 股股票期权激励计划》（以下简称 "2025 年 A 股股票期权计划"或"本次激励计划"）及相关资料进行核查核实后， 发表如下核查意见： 本次激励计划首次授予的激励对象包括本公司现任执行董事、职工董事、高 级管理人员，本集团（即本公司及控股子公司/单位，下同）现任中层管理人员、 核心技术（业务）人员，以及其他经董事会认定的对本集团整体业绩和持续发展 有直接影响的核心骨干人员；首次授予激励对象符合《公司法》《证券法》等法 1 由于部分首次授予拟激励对象不再属于本次激励计划激励对象范 ...

Group 1 - The weight loss drug sector experienced a decline of 2.54%, ranking among the top declines in concept sectors, with Changshan Pharmaceutical hitting a 20% limit down [1] - Major stocks in the weight loss drug sector that saw significant declines include Bibete, XinNuoWei, and Lepu Medical, while only three stocks, including Zhifei Biological, Yingte Group, and Yuningwei, recorded gains [1][2] - The weight loss drug sector faced a net outflow of 2.636 billion yuan from main funds, with 46 stocks experiencing outflows, and Changshan Pharmaceutical leading with a net outflow of 1.145 billion yuan [2] Group 2 - The top net outflow stocks in the weight loss drug sector include HengRui Medicine, GanLi Pharmaceutical, and Fosun Pharmaceutical, with net outflows of 393 million yuan, 175 million yuan, and 116 million yuan respectively [2][3] - Stocks with the highest net inflows include Zhifei Biological, Yipin Hong, and Shengnuo Biological, with net inflows of 82.1 million yuan, 22.7 million yuan, and 10.5 million yuan respectively [2][4] - The trading volume for Changshan Pharmaceutical was 8.08%, with a price drop of 20%, indicating significant trading activity despite the decline [2][3]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海復星醫藥(集團)股份有限公司 ( 於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | | 股份類別 | H | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02196 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 540,971,500 | | 10,969,000 | | 551,940,500 | | 增加 / 減少 (-) | | | | 0 | | 0 | | | | 本月底結存 | | | | 540,971,500 | | 10,969,000 | | 55 ...

Market Overview - The precision medicine sector experienced a decline of 1.77% on November 4, with TuoJing Life leading the drop [1][2] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable stock performances in the precision medicine sector included: - RenDu Bio (688193) closed at 52.90, up 1.05% with a trading volume of 7076.23 hands and a transaction value exceeding 36.99 million yuan [1] - TuoJing Life (300642) closed at 22.73, down 2.86% with a trading volume of 78,200 hands and a transaction value of 178 million yuan [2] - Other companies like DaAn Gene (002030) and Anke Bio (300009) showed minimal changes, with DaAn Gene remaining flat at 6.57 and Anke Bio down 0.55% to 10.84 [1][2] Capital Flow - The precision medicine sector saw a net outflow of 979 million yuan from institutional investors, while retail investors contributed a net inflow of 642 million yuan [2][3] - Specific stock capital flows indicated: - GuoMai Technology (002093) had a net inflow of 8.61 million yuan from institutional investors, while retail investors saw a net outflow of 15.98 million yuan [3] - TuoJing Life experienced minimal net inflow from institutional investors at 25,000 yuan, with retail investors also showing a slight outflow [3]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海復星醫藥(集團)股份有限公司 ( 於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02196 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 551,940,500 | RMB | | 1 RMB | | 551,940,500 | | 增加 / 減少 (-) | | | | 0 | | RMB | | 0 | | 本月底結存 | | | 551,940,500 | RMB | | 1 RMB | | 551,940,500 ...

Group 1 - Taifu Pump Industry has terminated the acquisition of 51% equity in Nanyang Huacheng [1] - Shareholder Fosun Pharma of Shanhe Pharmaceutical Auxiliary plans to reduce its stake by no more than 3% [1] - Several convertible bonds including Anji Convertible Bond, Longda Convertible Bond, and Oujing Convertible Bond will not undergo forced redemption [1][2] Group 2 - The following convertible bonds will not be adjusted: Oujing Convertible Bond, Longda Convertible Bond, and Tong 22 Convertible Bond [2] - New shares from Danna Biotechnology will be listed on the Beijing Stock Exchange [1] - North Mining Testing is also set to issue new shares on the Beijing Stock Exchange [1]

Core Viewpoint - The technology sector experienced significant declines, prompting a structural shift in market funds towards the innovative drug sector, which saw notable gains on the same day [1][3]. Group 1: Market Performance - The innovative drug sector rose by 3.91% amidst a downturn in the technology sector, successfully breaking through the 20-day moving average with increased trading volume, signaling positive market sentiment [3]. - The innovative drug sector had been in a downward trend since August but began to stabilize and form a bottom pattern in October [3]. Group 2: Multiple Sclerosis (MS) Market - The global market for MS drugs is projected to reach approximately $18.5 billion in 2024, with a significant portion of sales coming from third-generation products, particularly CD20 monoclonal antibodies [6]. - CD20 monoclonal antibodies are expected to account for over 60% of the MS drug sales in 2024, with the drug Ocrelizumab projected to generate sales of 7.64 billion yuan, reflecting a year-on-year growth of 7.4% [6]. Group 3: Chemical Pharmaceutical Industry - The global chemical pharmaceutical market grew from $1,038 billion in 2019 to $1,128 billion in 2023, with expectations to reach $1,156 billion in 2024 [10]. - In China, the chemical pharmaceutical market size was 883.9 billion yuan in 2022, with a year-on-year growth of 4.4%, projected to increase to 945 billion yuan by 2024 [10]. Group 4: Innovative Drug Sector Performance - In the first half of 2025, 21 A-share innovative drug companies reported revenues of 28.69 billion yuan, a year-on-year increase of 42%, while net losses narrowed significantly [11]. - The second quarter of 2025 saw these companies achieve revenues of 15.34 billion yuan, a 39% increase year-on-year, with net losses reduced by 97% [11][12]. Group 5: Future Outlook - Continued policy support for innovative drugs is expected to enhance performance, with an increase in product launches anticipated to drive revenue growth [15]. - The active business development (BD) transactions in the innovative drug sector in the first half of 2025 are expected to bolster the apparent performance of related companies [15].

Core Viewpoint - On October 31, six A-share listed companies disclosed their share reduction plans, with no companies announcing share increases on the same day [1]. Summary by Category Share Reduction Plans - Anke Zhidian: Shareholder Chen Xiaohui plans to reduce holdings by no more than 1% of the company's shares [2] - Shanhe Yaofu: Shareholder Fosun Pharma intends to reduce holdings by no more than 3.00% of shares [2] - Tuosida: Director and executive Huang Daibo plans to reduce holdings by no more than 0.95% of shares [2] - Saiwu Technology: Shareholder Dongyun Chuangtou plans to reduce holdings by no more than 1% of shares [2] - Dadi Xiong: Some directors and executives plan to collectively reduce holdings by no more than 0.75% of the company's shares [2] - Kanglongda: Shareholder Juyin Fund intends to reduce holdings by no more than 3.00% of shares [2]